Cathie Wood’s ARK Invest undertook significant portfolio adjustments on October 24, 2025, as it sold off shares of prominent U.S. tech stocks while simultaneously increasing its stakes in Chinese technology companies and the biotech sector. These transactions were revealed in ARK’s routine transaction report and reflect a strategic pivot in their investment approach.
Among the notable sales, the ARK Innovation ETF divested 23,717 shares of Advanced Micro Devices, amounting to $5.57 million, marking the largest single sale of the day. This decision comes as AMD’s stock gains momentum, bolstered by growing investor enthusiasm regarding the demand for artificial intelligence (AI) chips.
Additionally, ARK sold 39,077 shares of Shopify for $6.53 million, while also trimming positions in other tech stocks like Iridium Communications, Palantir Technologies, and Roblox. The sales of Palantir and Roblox, totaling over $9 million, reflect a reduction in tech exposure as investor interest veers towards AI and gaming initiatives.
In a contrasting move, ARK’s largest acquisition on this day was Baidu, with the purchase of 51,323 shares valued at $6.18 million. This investment spanned across three of ARK’s funds, enhancing its commitment to the Chinese internet giant, which is ramping up its efforts in AI technology and autonomous vehicles.
Just a day prior, on October 23, ARK had also purchased 68,939 shares of Alibaba for $11.4 million and 54,194 shares of Baidu for $6.34 million. These movements indicate ARK’s strategy to strengthen its portfolio in Chinese tech as the company navigates a shifting market landscape.
The biotech sector continued to attract ARK’s investment as well. The ARK Genomic Revolution ETF acquired 10,818 shares of Arcturus Therapeutics for $130,000 on October 24, further solidifying its position in this evolving field. Earlier, on October 23, ARK made a more substantial investment in Arcturus, buying 297,766 shares totaling $3.44 million.
The firm also invested $2.64 million in 1.35 million shares of Pacific Biosciences—firmly aligning with its focus on innovative gene sequencing technologies. Another significant purchase was 162,279 shares of 10x Genomics across two funds for $2.17 million, indicating a steadfast commitment to advancements in genomic research.
These recent portfolio adjustments by ARK indicate a keen interest in China’s tech landscape and a strategic emphasis on the biotech sector, all while scaling back on its investments in traditional U.S. tech giants. As the investment landscape continues to evolve, all eyes will be on ARK’s ability to navigate these shifts effectively.
